GRN-300 is under clinical development by Greenfire Bio and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRN-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Greenfire Bio overview
Greenfire Bio (Greenfire) is a life science company that builds a diversified product pipeline by developing early-stage assets. The company acquires, licenses, partners and invests in differentiated pre-clinical oearly clinical stage medical products to bridge the translational medicine gap and accelerate development. Its lead product candidate GRN-300, an orally bioavailable small molecule dual inhibitor of salt inducible kinases 2 and 3 (SIK2, SIK3) for the treatment ovarian cancer. Greenfire is also evaluating drugs targeting triple-negative breast cancer (TNBC), prostate, diffuse large B-cell lymphoma (DLBCL), melanoma and AML cancers. Greenfire is headquartered in Austin, Texas, the US.
For a complete picture of GRN-300’s drug-specific PTSR and LoA scores, buy the report here.